Verified

Professional Medical Education Grants

Novartis Pharmaceuticals Corporation

Important Notice: All grants and sponsorships must be submitted in NGCS by October 1, 2026. Submissions received by this date will receive a full review in NGCS. The new platform is scheduled to launch on November 16, 2026. Any submissions planned after October 1st, should be held until the new system is launched.

Our mission is to support high quality educational programs for US HCPs that will improve patient care.

We will evaluate professional medical education grant requests that are independent of commercial bias and non-promotional in nature. Professional medical education grants can be requested to support a variety of different activities, including live events, web-based education, and enduring materials.

We will accept grant requests for professional medical education programs from the following types of organizations:

Academic medical centers, medical universities
Hospitals, community health centers
Professional medical associations/societies
Accredited continuing medical education providers
Medical education companies

Preference will be given to non-profit organizations (societies or institutions), or requests that include collaborations with non-profit organizations.

We will also evaluate grant requests in support of research fellowships and awards from academic medical centers, medical universities and professional medical associations/societies. Individual recipients of these fellowships/awards should not have already been selected and Novartis can have no role in the selection of the recipient. Further Novartis funds cannot be used towards the physical award (eg plaque, trophy, etc).

AI Based Application Success Predictor

1. Alignment with Novartis strategic areas of interest ⭐⭐⭐⭐⭐

This is the most important predictor.

Competitive proposals should directly fit:

Novartis therapeutic areas
The specific funding opportunity
Current scientific priorities
Identified medical needs
Relevant drug-development opportunities

Novartis explicitly states that unsolicited research proposals are considered when they align with its strategic areas of interest and can enhance patient care or the development of innovative therapies.

2. Significant unmet medical need ⭐⭐⭐⭐⭐

Strong applications clearly explain the clinical problem and why existing approaches are insufficient.

Examples include:

Limited treatment options
Poor treatment response
Disease progression
Diagnostic gaps
Safety or tolerability problems
Treatment resistance
Unmet patient needs

The strongest proposals connect the research directly to an important healthcare problem.

3. Strong scientific merit and meaningful objectives ⭐⭐⭐⭐⭐

Novartis states that proposed investigator-initiated research must have meaningful scientific objectives and a valid study design.

Competitive proposals demonstrate:

Clear hypothesis
Important research question
Strong scientific rationale
Appropriate methodology
Relevant endpoints
Potential to generate useful medical knowledge

4. Potential to improve patient care ⭐⭐⭐⭐⭐

Strong projects should demonstrate how the findings could:

Improve treatment decisions
Improve patient outcomes
Improve understanding of disease
Optimize use of therapies
Identify appropriate patient populations
Address treatment gaps

Novartis specifically describes external research as a way to complement its own research and better understand the benefit/risk profile of therapies and opportunities to address unmet medical needs.

5. High-quality study design and methodology ⭐⭐⭐⭐⭐

Competitive IIT/IIR proposals should include:

Clearly defined objectives
Appropriate study population
Scientifically justified endpoints
Appropriate controls/comparators
Valid statistical methodology
Realistic timelines
Appropriate safety monitoring

Novartis emphasizes the requirement for a valid study design and protection of patient and animal safety and welfare.

6. Investigator expertise and ability to conduct the study ⭐⭐⭐⭐⭐

Novartis evaluates the qualifications of the proposed investigator and research team.

Important factors include:

Relevant scientific expertise
Clinical research experience
Previous publications
Experience in the therapeutic area
Ability to conduct clinical trials
Appropriate sub-investigators
Institutional resources

For certain Novartis programs, the company explicitly evaluates the PI's therapeutic-area expertise, clinical-trial experience, and available resources.

7. Translational and clinical relevance ⭐⭐⭐⭐⭐

The strongest research proposals establish a pathway from scientific findings to patient benefit.

Competitive projects may address:

Biomarkers
Precision medicine
Treatment response
New therapeutic strategies
Clinical outcomes
Real-world evidence
Safety and tolerability
Disease mechanisms relevant to therapy

This is particularly valuable when the research can help advance innovative therapies to more patients.

8. Independence and scientific credibility ⭐⭐⭐⭐☆

For investigator-initiated research, Novartis expects the external investigator to retain scientific responsibility.

A strong proposal clearly establishes:

Independent scientific concept
Investigator-led study design
Independent analysis
Publication plans
Appropriate regulatory responsibility
Transparent collaboration with Novartis where applicable

Novartis defines IITs as studies developed and sponsored by an independent investigator or academic sponsor.

9. Clear objectives, milestones, deliverables, and outcomes ⭐⭐⭐⭐☆

For general external funding requests, Novartis requires applications to describe:

Clearly defined purpose
Objectives
Deliverables
Milestones
Expected outcomes

This makes a proposal easier to evaluate and demonstrates that the requested funding will produce measurable results.

10. Regulatory compliance, ethics, and appropriate budget ⭐⭐⭐⭐☆

Competitive proposals must demonstrate:

IRB/ethics compliance where applicable
Patient safety
Data/privacy protections
Appropriate regulatory approvals
Realistic budget
Appropriate use of requested resources
Compliance with local laws and regulations

Novartis emphasizes that external funding must comply with applicable laws, regulations, and ethical standards.

Specialties

Others

Pharmaceuticals

Eligibility Requirements

In order to be considered, a complete grant application package must be submitted via the online portal at least 60 calendar days prior to the event date. If the completed grant application package is not received at least 60 days prior to the event date, the grant request may be denied. In addition, requests must be disease focused.

Required documents for submitting a Professional Medical Education Grant request.

Detailed budget
Proposal document: needs assessment, agenda, learning objectives, target audience, outcomes measurement plan, etc.
Current W9 (signed and dated)

Eligible Countries:

United States

Sponsor Details

Sponsor Institute/Organizations: Novartis Pharmaceuticals Corporation

Sponsor Type: Corporate/Non-Profit

Address: 1 Health Plaza, East Hanover, NJ 07936

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity